Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Exelixis, Inc.

A Decade of SG&A: Merck & Co., Inc. vs. Exelixis, Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Exelixis, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have consistently dwarfed those of Exelixis, averaging around 10 billion annually, a testament to its expansive global operations. In contrast, Exelixis, a smaller player, has seen its SG&A grow by over 900% from 2014 to 2023, reflecting its aggressive expansion and investment in growth. Notably, 2023 marked a peak for both companies, with Exelixis reaching approximately 543 million, while Merck maintained its robust spending at over 10 billion. This analysis highlights the diverse approaches in operational spending between a pharmaceutical giant and a rising star, offering insights into their strategic priorities and market positioning.